FCCC LOGO Faculty Publications
Beck TN , Deneka AY , Chai L , Kanach C , Johal P , Alvarez NJ , Boumber Y , Golemis EA , Laub GW
An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion
BMC Cancer. 2019 Jun 24;19(1) :614
PMID: 31234819    PMCID: PMC6589887   
Back to previous list
BACKGROUND: Malignant pleural effusion (MPE) is a devastating sequela associated with cancer. Talc pleurodesis is a common treatment strategy for MPE but has been estimated to be unsuccessful in up to 20-50% of patients. Clinical failure of talc pleurodesis is thought to be due to poor dispersion. This monograph reports the development of a foam delivery system designed to more effectively coat the pleural cavity. METHODS: C57BL/6 mice were injected with Lewis lung carcinoma (LL/2) cells intrapleurally to induce MPE. The mice then received either normal saline (NS) control, foam control (F), talc slurry (TS, 2 mg/g) or talc foam (TF, 2 mg/g). Airspace volume was evaluated by CT, lungs/pleura were collected, and percent fibrosis was determined. RESULTS: The TF group had significantly better survival than the TS group (21 vs 13.5 days, p < 0.0001). The average effusion volume was less in the talc groups compared to the control group (140 vs 628 muL, p < 0.001). TF induced significant lung fibrosis (p < 0.01), similar to TS. On CT, TF significantly (p < 0.05) reduced loss of right lung volume (by 30-40%) compared to the control group. This was not seen with TS (p > 0.05). CONCLUSIONS: This report describes using a novel talc foam delivery system for the treatment of MPE. In the LL/2 model, mice treated with the TF had better survival outcomes and less reduction of lung volume than mice treated with the standard of care TS. These data provide support for translational efforts to move talc foam from animal models into clinical trials.
1471-2407 Beck, Tim N ORCID: http://orcid.org/0000-0003-4022-0596 Deneka, Alexander Y Chai, Louis Kanach, Colin Johal, Priya Alvarez, Nicolas J Boumber, Yanis Golemis, Erica A Laub, Glenn W F30 CA180607/National Cancer Institute P30 CA006927/National Institutes of Health R01 CA218802/National Institutes of Health R21 CA223394/National Institutes of Health Journal Article England BMC Cancer. 2019 Jun 24;19(1):614. doi: 10.1186/s12885-019-5777-z.